

B2 ~~20~~¹¹23. A nucleoside of claim 7 wherein R¹ is hydrogen.

~~20~~¹²24. A nucleoside of claim 8 wherein R¹ is hydrogen.

Remarks

Claims 11 and 12 are amended to describe the pharmaceutical method and the pharmaceutical composition as useful specifically for the treatment of Herpes infections. The amendments follow the pattern established in the parent case, now U.S. Patent 4,692,434, and are made in response to the rejection of Claims 11 and 12 under 35 U.S.C. 112.

The amendment to Claim 1 removes from Claim 1 the subject matter which was allowed and issued in the parent case, which is now U.S. Patent 4,692,434. The parent application was confined to that scope of subject matter as the result of a restriction requirement, and it is therefore proper to amend the present claims to exclude that subject matter.

Claims 13-22 have been canceled as the result of the restriction requirement which was given by telephone in this case. Applicant's attorney was told to restrict between Group I -- Claims 1-12 -- and Group II -- Claims 13-22. Group I was elected by telephone, with traverse, and Applicant now affirms that election and cancels the non-elected claims.

Entry of new Claims 23 and 24 is requested. The new claims are supported in particular by Example 8. The claims are dependent on and fully embraced by Claim 1, and do not affect the scope of the search. It is believed that entry of them is entirely proper at this time.

52